Core Insights - CorMedix Inc. announced that its product DefenCath has received an Innovative Technology designation from Vizient, indicating its potential impact on patient care and healthcare operations [1][4] - DefenCath is the first FDA-approved antimicrobial catheter lock solution in the U.S., specifically designed to reduce catheter-related bloodstream infections in adult patients undergoing chronic hemodialysis [3][5] - In clinical studies, DefenCath demonstrated a 71% reduction in the risk of developing catheter-related bloodstream infections compared to control [3] Company Overview - CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, including DefenCath for preventing catheter-related bloodstream infections [5] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products [5] - The company has ongoing clinical studies for DefenCath in various patient populations and intends to expand its applications [6] Industry Context - Vizient, the organization granting the Innovative Technology designation, represents a diverse client base with approximately $156 billion in annual purchasing volume, including academic medical centers and community hospitals [4] - The Innovative Technology designation is awarded based on evaluations by healthcare experts for products that enhance clinical care and improve business operations [2]